Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension

https://doi.org/10.20996/1819-6446-2020-11-03

Full Text:

Abstract

Aim. To evaluate the single pill combination with lisinopril, amlodipine and indapamide ability in additional angioprotection achievement in patients with arterial hypertension and high pulse wave velocity (PWV) regardless on previous antihypertensive therapy (AHT).
Material and methods. To the open non-randomized study duration 12 weeks 40 patients were included taking triple AHT during 6 months. All participants underwent ambulatory 24 hour blood pressure (BP) monitoring, applanation tonometry (augmentation index and central BP), pulse wave velocity assessment, laboratory tests (HbA1c, serum uric acid, high sensitive C-reactive protein [hsCRP], serum uric acid).
Results. We observed additional systolic BP (SBP) and diastolic BP (DBP) reduction by 16.9% and 22.11% on lisinopril, amlodipine and indapamide single pill combination. Lisinopril, amlodipine and indapamide single pill combination decreased 24 h mean SBP by 16.77%, and 24 h mean DBP -23.5% (ABPM data), PWV by 19.7%, augmentation index by 14.81%, central SBP by 11.9% (p<0,05). There were positive changes in hsCRP level (-13.0%, p<0.05) and serum uric acid (-9.0%, p<0.05).
Conclusion. Lisinopril, amlodipine and indapamide single pill combination provided control BP, arterial elastic properties improving (augmentation index, PWV, central BP) and favorable influence on inflammation and serum uric acid level.

About the Authors

S. V. Nedogoda
Volgograd State Medical University
Russian Federation

Sergey V. Nedogoda - MD, PhD, Professor, Head of the Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



T. N. Sanina
Volgograd State Medical University
Russian Federation

Tatiana N. Sanina - MD, PhD, Associate Professor, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



V. V. Tsoma
Volgograd State Medical University
Russian Federation

Vera V. Tsoma - MD, PhD, Associate Professor, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



A. A. Ledyaeva
Volgograd State Medical University
Russian Federation

Alla A. Ledyaeva - MD, PhD, Assistant, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



E. V. Chumachek
Volgograd State Medical University
Russian Federation

Elena V. Chumachek - MD, PhD, Associate Professor, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



A. S. Salasyuk
Volgograd State Medical University
Russian Federation

Alla S. Salasyuk - MD, PhD, Associate Professor, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



D. S. Vlasov
Volgograd State Medical University
Russian Federation

Daniil S. Vlasov - Post-graduate Student, Chair of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.
Pavshikh Bortsov Pl. 1, Volgograd, 400131.



O. I. Bychkova
Federal Security Service of Russia (medical department) for the Volgograd Region
Russian Federation

Olga I. Bychkova - MD, PhD, Head of Military Fedical Service, Federal Security Service of Russia of the Volgograd Region.
Lesogorskaya ul. 67A, Volgograd, 400048.



References

1. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;00: 1-98. DOI:10.1093/eurheartj/ehy339.

2. Shlyahto E.V., Kobalava Zh.D., Konradi A.O., et al. 2020 Guidelines for the management of arterial hypertension [cited by Oct 1 5, 2020]. Available from: https://scardio.ru/content/Guidelines/ Clinic_rek_AG_2020.pdf (In Russ.)

3. Nemcsik J., Cseprekal O., Tisler A. Measurement of Arterial Stiffness: A Novel Tool of Risk Stratification in Hypertension. Adv Exp Med Biol. 2017;956:475-88. DOI:10.1007/5584_2016_78.

4. Chen X., Huang B., Liu M., Li X. Effects of different types of antihypertensive agents on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. J Thorac Dis. 2015;7(12):2339-47. DOI:10.3978/j.issn.2072-1439.2015.12.58.

5. Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118-23. DOI:10.1016/j.amjhyper.2003.09.012.

6. Mackenzie I.S., McEniery C.M., Dhakam Z., et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54(2):409-13. DOI:10.1161/HYPERTENSIONAHA.109.133801.

7. Elliott WJ., Childers WK. Should в blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? Curr Cardiol Rep. 2011;13(6):507-16. DOI:10.1007/s11886-011-0216-z.

8. Hirata K., Vlachopoulos C., Adji A., O'Rourke M.F. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hy-pertens. 2005;23(3):551-6. DOI:10.1097/01.hjh.0000160211.56103.48.

9. London G.M., Pannier B., Guerin A.P., et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90(6):2786-96. DOI:10.1161/01.cir.90.6.2786.

10. Dhakam Z., McEniery C.M., Yasmin A., еt al. Atenolol and eprosartan: differential effects oncentral blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19(2):214-9. DOI:10.1016/j.amjhyper.2005.08.007.

11. Mahmud A., Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14:541-6. DOI:10.1038/sj.jhh.1001053.

12. Sharman J.E., Stanton T., Reid C.M., et al. Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). Contemp Clin Trials. 2017;62:37-42. DOI:10.1016/j.cct.2017.08.010.

13. Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55(6):1314-22. DOI:10.1161/HYPERTENSIONAHA.109.148999.

14. Matsui Y., O'Rourke M.F., Hoshide S., et al. Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE Study. Atherosclerosis. 2011;215(1):184-8. DOI:10.1016/j.atherosclerosis.2010.12.022.

15. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentrerandomised controlled trial. Lancet. 2005;366:895-906. DOI:10.1016/S0140-6736(05)67185-1.

16. Manisty C.H., Zambanini A., Parker K.H., et al. Differences in the magnitude ofwave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. Hypertension. 2009;54(4):724-30. DOI:10.1161/HYPERTENSIONAHA.108.125740.

17. Guerin A.P., Blacher J., Pannier B. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation. 2001;103(7):987-92. DOI:10.1161/01.cir.103.7.987.

18. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107(3):363-9. DOI:10.1161/01.cir.0000053730.47739.3c.

19. Roberts E.R., Green D., Kadam U.T. Chronic condition comorbidity and multidrug therapy in general practice populations: a cross-sectional linkage study. BMJ Open. 2014;4(7):e005429. DOI:10.1136/bmjopen-2014-005429.

20. Doupis J., Papanas N., Cohen A., et al. Pulse Wave Analysis by Applanation Tonometry for the Measurement of Arterial Stiffness. Open Cardiovasc Med J. 2016;31(10):188-95. DOI:10.2174/1874192401610010188.

21. Van Bortel L.M., De Backer T., Segers P. Standardization of arterial stiffness measurements make them ready for use in clinical practice. Am J Hypertens. 2016;29(11):1234-6. DOI:10.1093/ajh/hpw084.

22. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-25. DOI:10.1161/CIRCULATIONAHA.105.595496.

23. Takami T., SaitoY. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study. Vasc Health Risk Manag. 2011;7:383-90. DOI:10.2147/VHRM.S21991.

24. Kastanayan A.A., Zheleznjak E.I., Hagush A.K., et al. The relationship between blood pressure variability and cardiovascular remodeling in hypertension developed in the elderly. Arterial Hypertension. 2016;22(4):389-400. (In Russ.)

25. Vlachopoulos C., Xaplanteris P., Vyssoulis G., et al. Association of Serum Uric Acid Level With Aortic Stiffness and Arterial Wave Reflections in Newly Diagnosed, Never-Treated Hypertension. Am J Hy-pertens. 2011;24(1):33-9. DOI:10.1038/ajh.2010.111.

26. Choi H.K., Soriano L.C., Zhang Y. et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. DOI:10.1136/bmj.d8190.

27. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17(5-6):397-414. DOI:10.1023/b:card.0000015855.02485.e3.

28. Barzilay J.I, Davis B.R., Pressel S.L., et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study Circ Cardiovasc Qual Outcomes. 2012;5(2):153-62. DOI:10.1161/CIRCOUTCOMES.111.962522.


For citation:


Nedogoda S.V., Sanina T.N., Tsoma V.V., Ledyaeva A.A., Chumachek E.V., Salasyuk A.S., Vlasov D.S., Bychkova O.I. Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension. Rational Pharmacotherapy in Cardiology. 2020;16(6):931-937. (In Russ.) https://doi.org/10.20996/1819-6446-2020-11-03

Views: 331


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)